Clinical Trial Update: A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update on a Phase 1/2 study evaluating [177Lu]Lu-DOTA-TATE in combination with carboplatin, etoposide, and atezolizumab for newly diagnosed exten…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extensive-stage Small Cell Lung Cancer

Drugs mentioned

• Atezolizumab (atezolizumab)
• CARBOPLATIN (Carboplatin)
• Etoposide (Etoposide)
• [177Lu]Lu-DOTA-TATE (Lutetium-177 DOTA-TATE)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Extensive Stage Small Cell Lung Cancer | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING